All In Biotech

Drug Trial Radar · NCT01494688

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

217

Actual

Start

Dec 20, 2011

Primary completion

Feb 7, 2018

Study completion Feb 7, 2018

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in participants with advanced solid tumors which are not amenable to standard treatment. In Part I (Dose Escalation), multiple ascending doses of RO5509554 will be administered as monotherapy in participants with solid tumors. Participants with locally advanced and/or metastatic ovarian (including fallopian tube) and breast carcinoma will receive multiple ascending doses of RO5509554 in combination with paclitaxel. In Part II (Expansion Cohort), RO5509554 will be administered as monotherapy to participants with locally advanced and/or metastatic Pigmented Villonodular Synovitis (PVNS)/Tenosynovial Giant Cell Tumor (TGCT), soft tissue sarcoma or malignant mesothelioma, ovarian (including fallopian tube), endometrial or breast cancer and pancreatic cancer. Participants with Human Epidermal Growth Factor Receptor 2 (HER2)/neu negative breast cancer will receive RO5509554 in combination with paclitaxel. Anticipated time on study treatment is until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Conditions

  • Advanced Solid Tumors

Interventions

  • PaclitaxelDrug

    Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.

  • RO5509554Drug

    RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse EventsTime frame: Baseline up to 28 days after last dose (approximately 48 months)
  2. Part 1: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of RO5509554 as a Single Agent and in Combination With PaclitaxelTime frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Univ of Pennsylvania Med Ctr

    Philadelphia, Pennsylvania

  • Institut Bergonie; Oncologie

    Bordeaux, France

  • Centre Leon Berard; Departement Oncologie Medicale

    Lyon, France

  • Institut Curie; Oncologie Medicale

    Paris, France

  • Ico Rene Gauducheau; Oncologie

    Saint-Herblain, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.